Faron Pharmaceuticals Ltd has announced the grant of 34,000 options over ordinary shares in the company under its Share Option Plan 2019. The options are exercisable between November 9, 2024, and November 9, 2028, with 25% vesting per annum over four years. The exercise price for the options allocated under the Share Option Plan is €3.53 per share, while the exercise price for options allocated under the US sub plan is €3.35 per share. The granted options represent 0.05% of the fully diluted ordinary share capital of the company. Among the options granted are 30,000 options to director Christine Roth.